Imiquimod
- Generic Name
- Imiquimod
- Brand Names
- Aldara, Vyloma, Zyclara
- Drug Type
- Small Molecule
- Chemical Formula
- C14H16N4
- CAS Number
- 99011-02-6
- Unique Ingredient Identifier
- P1QW714R7M
- Background
Imiquimod is an immune response modifier that acts as a toll-like receptor 7 agonist. Imiquimod is commonly used topically to treat warts on the skin of the genital and anal areas. Imiquimod does not cure warts, and new warts may appear during treatment. Imiquimod does not fight the viruses that cause warts directly, however, it does help to relieve and cont...
- Indication
For the topical treatment of clinically typical, nonhyperkeratotic, nonhypertrophic actinic keratoses on the face or scalp in immunocompetent adults. Also indicated for the treatment of external genital and perianal warts/condyloma acuminata in individuals 12 years old and above.
- Associated Conditions
- Actinic Keratoses of the face, Actinic Keratoses of the scalp, Condylomata Acuminata, Herpes Simplex Infections, Molluscum Contagiosum, Superficial Basal Cell Carcinoma
- Associated Therapies
- -
Safety and Efficacy Study of SL-701, a Glioma-Associated Antigen Vaccine To Treat Recurrent Glioblastoma Multiforme
- First Posted Date
- 2014-03-05
- Last Posted Date
- 2024-03-27
- Lead Sponsor
- Stemline Therapeutics, Inc.
- Target Recruit Count
- 74
- Registration Number
- NCT02078648
- Locations
- 🇺🇸
Cleveland Clinic, Cleveland, Ohio, United States
🇺🇸Baylor Charles A Sammons Cancer Center, Dallas, Texas, United States
🇺🇸University of Alabama, Birmingham, Alabama, United States
Imiquimod, Fluorouracil, or Observation in Treating HIV-Positive Patients With High-Grade Anal Squamous Skin Lesions
- Conditions
- Interventions
- First Posted Date
- 2014-02-11
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- AIDS Malignancy Consortium
- Target Recruit Count
- 91
- Registration Number
- NCT02059499
- Locations
- 🇺🇸
Emory University, Atlanta, Georgia, United States
🇺🇸Laser Surgery Care, New York, New York, United States
🇺🇸Weill Medical College of Cornell University, New York, New York, United States
A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of LFX453
- Conditions
- Interventions
- First Posted Date
- 2014-02-03
- Last Posted Date
- 2015-05-15
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 41
- Registration Number
- NCT02052687
- Locations
- 🇬🇧
Novartis Investigative Site, Mid Glamorgan, United Kingdom
Photoaging Treatment With Imiquimod
- First Posted Date
- 2013-09-05
- Last Posted Date
- 2013-09-05
- Lead Sponsor
- CES University
- Target Recruit Count
- 17
- Registration Number
- NCT01935310
- Locations
- 🇨🇴
Centro de servicios CES Sabaneta, Medellín, Antioquia, Colombia
Combination Vaccine Immunotherapy (DRibbles) for Patients With Definitively-Treated Stage III Non-small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2013-07-26
- Last Posted Date
- 2017-07-06
- Lead Sponsor
- UbiVac
- Target Recruit Count
- 12
- Registration Number
- NCT01909752
- Locations
- 🇺🇸
LSU Stanley S. Scott Cancer Center, New Orleans, Louisiana, United States
🇺🇸Providence Cancer Center, Portland, Oregon, United States
Primary Imiquimod Treatment Versus Surgery for Vulvar Intraepithelial Neoplasia
- Conditions
- Interventions
- First Posted Date
- 2013-05-23
- Last Posted Date
- 2021-04-14
- Lead Sponsor
- Medical University of Graz
- Target Recruit Count
- 110
- Registration Number
- NCT01861535
- Locations
- 🇦🇹
Department of Gynecology and Obstetrics, Medical University of Innsbruck, Innsbruck, Austria
🇦🇹Dep. of Gynecology, Krankenhaus Barmherzige Brüder Graz, Graz, Styria, Austria
🇦🇹Department of Obstetrics and Gynecology/ Medical University of Graz, Graz, Austria
Dendritic Cell (DC) Vaccine for Malignant Glioma and Glioblastoma
- First Posted Date
- 2013-03-11
- Last Posted Date
- 2022-07-20
- Lead Sponsor
- Macarena De La Fuente, MD
- Target Recruit Count
- 20
- Registration Number
- NCT01808820
- Locations
- 🇺🇸
University of Miami, Miami, Florida, United States
Dendritic Cell Vaccine for Children and Adults With Sarcoma
- Conditions
- Interventions
- First Posted Date
- 2013-03-04
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- Macarena De La Fuente, MD
- Target Recruit Count
- 19
- Registration Number
- NCT01803152
- Locations
- 🇺🇸
University of Miami, Miami, Florida, United States
Immunotherapy for Recurrent Ependymomas in Children Using Tumor Antigen Peptides with Imiquimod
- First Posted Date
- 2013-02-20
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- James Felker
- Target Recruit Count
- 24
- Registration Number
- NCT01795313
- Locations
- 🇺🇸
Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States
Imiquimod and Tumor Lysate Vaccine Immunotherapy in Adults With High Risk or Recurrent Grade II Gliomas
- Conditions
- Interventions
- First Posted Date
- 2012-09-05
- Last Posted Date
- 2020-02-24
- Lead Sponsor
- Frank Lieberman
- Target Recruit Count
- 19
- Registration Number
- NCT01678352
- Locations
- 🇺🇸
University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.